

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 26 avril 2023 14:12

Laboratory Information

Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	Enzootic bovine leukosis
Address of laboratory:	Al. Partyzantow str. 57 24-100 Pulawy POLAND
Tel.:	+48 81 8863114
E-mail address:	jkuzmak@piwet.pulawy.pl
Website:	www.piwet.pulawy.pl
Name (including Title) of Head of Laboratory (Responsible Official):	Stanislaw Winiarczyk, DVM, PhD, Professor, Director General of NVRI
Name (including Title and Position) of WOA Reference Expert:	Jacek Kuzmak, DVM, PhD, Professor, Head of Department of Biochemistry of NVRI
Which of the following defines your laboratory? Check all that apply:	N/A Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
ELISA (blocking or screening format)	YES	611	0
Direct diagnostic tests		Nationally	Internationally
PCR (neted PCR and real-time)	YES	45	0

PCR)

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

7. Did your laboratory validate diagnostic methods according to WOA Standards for the designated pathogen or disease?

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOA Standards for the designated pathogen or disease?

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

NAME OF THE WOA MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
GREECE	Interpretation serological test results	By email
CROATIA	Query regarding participation in PT	By email
BOSNIA AND HERZEGOVINA	Query regarding participation in PT	By email
SPAIN	Technical consultancy for interpretation serological test results	By email
UNITED STATES OF AMERICA	Query regarding BLV positive reference serum	By email

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Molecular analysis of BLV isolates from US and Canada	3 months	Preparation of scientific report	University of Calgary, Michigan University	CANADA UNITED STATES OF AMERICA
Prevalence of bovine retroviruses (BLV, BIV and BFV) in dairy cattle from Pakistan	12 months	New epidemiological data on seroprevalence of infection with bovine retroviruses	Animal Quarantine Department, Peshawar, Pakistan	PAKISTAN
Circulation of BLV genotypes in dairy cattle and camels from Kazakhstan	10 months	Molecular epidemiology of infection with BLV in cattle and camels from Kazakhstan	Kazah Scientific Veterinary Institute, Almaty, Kazakhstan	KAZAKHSTAN

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1. Sultanov A, Rola-Luszczak M., Mamonova S., Rylo A., Osinski Z., Sadukassova M., Bashenova E., Kuzmak J. Molecular Characterization of Bovine Leukemia Virus with the Evidence of a New Genotype Circulating in Cattle from Kazakhstan. *Pathogens*, 2022 Jan 28;11(2):180. doi: 10.3390/pathogens11020180.

2. Szczotka M., Kuzmak J. Expression of Bovine Leukaemia Virus (BLV) Gp51 Protein in Blood and Milk Cells of Cows with Leukosis. *J. Vet. Res.* 2022 Jul 30;66(3):305-315. doi: 10.2478/jvetres-2022-0035. eCollection 2022 Sep.

b) International conferences:

"An immunoinformatics study on the Gag of Bovine Leukemia Virus reveals BoLA-DR restricted CD4 T cell epitopes on matrix, capsid and nucleocapsid proteins", Authors: Aneta Pluta, Frank van der Meer, Sulav Shrestha, Jacek Kuźmak. 6th Congress of the European Association of Veterinary Laboratory Diagnosticians (EAVLD) - October 24-26, 2022 Sevilla, Spain.

c) National conferences:

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
PN-ENIOS/IEC 17025:2018-2	pdf	certificate AB 1090.pdf
PN-ENIOS/IEC 17025:2018-2	pdf	scope AB 1090.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
ELISA , Agar Gel Immunodiffusion Test	PCA (Polish Accreditation Center) which is a part of ALAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

No

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA H?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA H?

No

TOR10: NETWORK WITH WOA H REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA H Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOA H Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOA H Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOAHP REF. LABS/ ORGANISING WOAHP REF. LAB.
Detection of proviral DNA of BLV	Reference Laboratory at NVRI prepared the DNA samples	Two	WOAH Reference Laboratory for EBL at APHA Weybridge

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

TITLE OF THE PROJECT OR CONTRACT	SCOPE	NAME(S) OF RELEVANT WOAHP REFERENCE LABORATORIES
Enzootic bovine leukosis: OIE Laboratory Twinning Program between Poland and Kazakhstan with the collaboration of the United Kingdom	To build capacity of KazSRVI to be able to provide key elements of a WOAHP Reference Laboratory mandated in respect to EBL	WOAH Reference Laboratory for Enzootic Bovine Leukosis - APHA, Weybridge, UK

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Region(s) of participating WOAHP Member Countries
BLV antibody detection in serum samples by ELISA and AGID	Organizer and provider of serum samples	14	Europe

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

No

29. Additional comments regarding your report:

No